Annualized joint Bleeding Rate (AjBR) · adults and children with hemophilia A or B with inhibitors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with hemophilia A or B with inhibitors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Number of total bleeds per year or bleeding frequency · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Target joint bleeding rate · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Overall survival at 5‐year · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Event‐free survival · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Treatment‐related mortality · women with early poor prognosis breast cancer
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Second cancers at 4 ‐ 9‐year median · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Outcomes** · people with Acute Respiratory Distress Syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (at 30 days or until hospital discharge) · people with Acute Respiratory Distress Syndrome
It is very uncertain whether high‐frequency oscillation changes mortality (at 30 days or until hospital discharge) compared with conventional ventilation (very low certainty).
1 finding from 1 review
Mortality (at 6 months) · people with Acute Respiratory Distress Syndrome
It is very uncertain whether high‐frequency oscillation changes mortality (at 6 months) compared with conventional ventilation (very low certainty).
1 finding from 1 review
Treatment failure · people with Acute Respiratory Distress Syndrome
It is very uncertain whether high‐frequency oscillation changes treatment failure compared with conventional ventilation (very low certainty).
1 finding from 1 review